Multimodal Imaging Assessment of the Inflammatory Atheromatous Plaque

Sponsor
University of Lausanne Hospitals (Other)
Overall Status
Recruiting
CT.gov ID
NCT01608516
Collaborator
Swiss Heart Foundation (Other)
20
1
1
128
0.2

Study Details

Study Description

Brief Summary

The present study aims at assessing the ability of 68Ga-NODAGA-RGD PET/CT for the detection of inflammatory atheromatous plaques in the carotid arteries, compared to 18F-FDG PET/CT, MRI and US and to determine the contribution of each imaging technique. Current gold standard for inflammation is histopathology.

Hypothesis : 68Ga-NODAGA-RGD might give a better initial evaluation of patients with atheromatous plaques in the carotid artery eligible for endarterectomy.

Condition or Disease Intervention/Treatment Phase
  • Radiation: 68Ga-NODAGA-RGD PET/CT
Phase 1/Phase 2

Detailed Description

Patients with indication for endarterectomy will be presented the present protocol. If inclusion criteria are fulfilled, patients will have a 18F-FDG PET/CT + carotid US performed 6 to 2 days before endarterectomy and 68Ga-NODAGA-RGD PET/CT + MRI performed the day before endarterectomy. Histopathological sample will be analyzed to measure plaque inflammation.

All imaging results and histopathology results will be pooled and compared.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Multimodal Assessment of the Inflammatory Atheromatous Plaque : Comparison Between 68Ga-NODAGA-RGD PET/CT, 18F-FDG PET/CT, MRI AND US
Actual Study Start Date :
Apr 1, 2012
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: 68Ga-NODAGA-RGD radiotracer

All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT, a MRI and a US.

Radiation: 68Ga-NODAGA-RGD PET/CT
200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired

Outcome Measures

Primary Outcome Measures

  1. Comparison of each method of imaging for the detection of inflammatory atheromatous plaques [Within1 month of endarterectomy]

    The potential of each of the methods of imaging for the detection of inflammatory atheromatous plaques will be compared. For that purpose, the capacity of every criterion of primary assessment to determine the presence of an unstable plaque will be studied compared with the histopathological sample.

Secondary Outcome Measures

  1. Comparison of AUC of the imaging methods [Within1 month of endarterectomy]

    A comparison of the AUC will be realized to determine the superiority of a method compared with the other one, by a non parametric test comparing AUC , ROC curves respectively.

  2. Analysis of histopathological sample of endarterectomy [Within1 month of endarterectomy]

    The histopathological analysis will be the degree of local inflammation estimated by the macrophagic infiltration as well as the degree of neovascularization.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • age <= 85 years

  • Karnofsky >= 80%

  • patient with indication ofr carotid endarterectomy

  • signed consent form

Exclusion Criteria:
  • indication for surgery other than endarterectomy <14 days

  • contraindication to surgery

  • contraindication to MRI

  • contraindication to gadolinium injection (stage 4/5 kidney insufficiency, GFR<30ml/min/1.73m2)

  • pregnancy, breastfeeding

  • lack of discernment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier Universitaire Vaudois Lausanne Vaud Switzerland 1011

Sponsors and Collaborators

  • University of Lausanne Hospitals
  • Swiss Heart Foundation

Investigators

  • Principal Investigator: John O. Prior, PhD, MD, Lausanne University Hospitals

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
John O. Prior, Chief of Department of Nuclear Medicine, University of Lausanne Hospitals
ClinicalTrials.gov Identifier:
NCT01608516
Other Study ID Numbers:
  • 80/10
First Posted:
May 31, 2012
Last Update Posted:
Jun 15, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by John O. Prior, Chief of Department of Nuclear Medicine, University of Lausanne Hospitals
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 15, 2022